【Neurelis-Product NRL-1】Neurelis Announces Commercial Availability of VALTOCO (diazepam nasal spray) for Seizure Cluster Rescue

Partner News

03ndMarch 2020 – Neurelis, Inc. issued an announcement, which is summarized as follows

 — VALTOCO is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older

 — Copay and patient assistance program to be provided by Neurelis for eligible VALTOCO patients

 Neurelis, Inc., today announced that the commercial availability of VALTOCO® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.

 Chuck DeWildt, Chief Commercial Officer at Neurelis, announced Maxor Specialty Pharmacy has been selected as the national pharmacy provider and has already begun filling patient prescriptions. “VALTOCO is the first commercial product for Neurelis and we are now rapidly building our commercial organization,” DeWildt said. “Working with Maxor allows us to expedite the availability of VALTOCO for patients, healthcare providers and care partners who need it in advance of VALTOCO availability in retail pharmacies in the near future.” He added that Maxor will be able to serve all patients regardless of the type of insurance (commercial, private insurance, Medicaid or Medicare).

 In an effort to support patients, Neurelis is offering a VALTOCO copay assistance program through which eligible patients could pay as little as $20 for the prescription. Neurelis has also set up a patient assistance program in which eligible patients who do not have insurance may qualify for additional assistance.

The original website link